Mantle Cell Lymphoma Overview
48 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

Which statement is true regarding the presentation of mantle cell lymphoma in peripheral blood?

  • Circulating lymphoma cells are rarely visible.
  • It typically presents with a uniform population of cells.
  • Cytoplasmic granules are commonly present in affected cells.
  • Pleomorphic cells with irregular nuclei are a characteristic feature. (correct)

    • What is the common pattern of bone marrow infiltration in mantle cell lymphoma?

  • Infiltration is primarily diffuse without distinct shapes.
  • Peritrabecular infiltration is the most common.
  • Infiltration is usually uniform throughout the marrow.
  • Interstitial or focal infiltration patterns are observed. (correct)

    • Which of the following immunophenotypic markers is characteristically not expressed in mantle cell lymphoma?

  • CD10 (correct)
  • CD22
  • CD19
  • CD5

    • What distinguishes the blastoid variant of mantle cell lymphoma from the non-blastoid variant?

    <p>Presence of a 'starry sky' appearance. (C)</p> Signup and view all the answers

    Which characteristic nuclear feature is observed in some cells of the blastoid variant of mantle cell lymphoma?

    <p>Cleft nuclei and cytoplasmic vacuoles. (A)</p> Signup and view all the answers

    Which of the following statements about the cytoplasmic features of mantle cell lymphoma cells is correct?

    <p>Cytoplasmic vacuoles and granules can appear variably. (C)</p> Signup and view all the answers

    What is the distinctive cytogenetic feature of mantle cell lymphoma?

    <p>t(11;14) translocation (A)</p> Signup and view all the answers

    How would the chromatin pattern in mantle cell lymphoma cells typically present?

    <p>Varies, with some showing a diffuse pattern and others showing condensation. (D)</p> Signup and view all the answers

    Which age group is primarily affected by mantle cell lymphoma?

    <p>Middle-aged and older individuals, median age 60 years (D)</p> Signup and view all the answers

    What is observed in the bone marrow of patients with mantle cell lymphoma upon trephine biopsy?

    <p>Lymphoma cells often have irregular and cleaved nuclei. (A)</p> Signup and view all the answers

    What is the median survival rate for mantle cell lymphoma?

    <p>3-4 years (C)</p> Signup and view all the answers

    Which of the following is commonly associated with advanced stage mantle cell lymphoma?

    <p>Lymphadenopathy and splenomegaly (C)</p> Signup and view all the answers

    What factor is crucial for determining optimal treatment approaches for mantle cell lymphoma?

    <p>Risk stratification at diagnosis (D)</p> Signup and view all the answers

    How does peripheral blood involvement affect prognosis in mantle cell lymphoma?

    <p>It is associated with a worse prognosis (C)</p> Signup and view all the answers

    What is a significant characteristic of leukemic non-nodal mantle cell lymphoma?

    <p>It tends to be clinically indolent (A)</p> Signup and view all the answers

    Which of the following locations is common for extranodal involvement in mantle cell lymphoma?

    <p>Waldeyer's ring (C)</p> Signup and view all the answers

    What is the hallmark cytogenetic abnormality in mantle cell lymphoma?

    <p>t(11;14) (q13.3;q32) (B)</p> Signup and view all the answers

    Which marker is considered a diagnostic marker for mantle cell lymphoma?

    <p>Cyclin D1 (C)</p> Signup and view all the answers

    Which method is primarily used for detecting the t(11;14) translocation?

    <p>FISH (C)</p> Signup and view all the answers

    What is the typical status of IGHV genes in mantle cell lymphoma cells?

    <p>Unmutated (C)</p> Signup and view all the answers

    Which secondary genetic abnormality is commonly associated with mantle cell lymphoma?

    <p>Loss of CDKN2A (D)</p> Signup and view all the answers

    Which of the following markers is typically negative in mantle cell lymphoma?

    <p>CD10 (A)</p> Signup and view all the answers

    Which statement about cyclin D1 is true in the context of mantle cell lymphoma?

    <p>It is overexpressed due to t(11;14). (B)</p> Signup and view all the answers

    In mantle cell lymphoma, the presence of which marker is variable and generally weak?

    <p>CD23 (A)</p> Signup and view all the answers

    What genetic alteration is characteristic of mantle cell lymphoma (MCL) but absent in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

    <p>t(11;14) translocation (B)</p> Signup and view all the answers

    Which marker is typically positive in mantle cell lymphoma (MCL) but negative in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

    <p>Cyclin D1 (D)</p> Signup and view all the answers

    In the context of mantle cell lymphoma (MCL), what unique challenge arises from a subset expressing CD23?

    <p>It makes the differential diagnosis with CLL/SLL more difficult. (B)</p> Signup and view all the answers

    What percentage of mantle cell lymphoma (MCL) cases are known to be weakly positive for CD23?

    <p>13% (A)</p> Signup and view all the answers

    What distinguishes CD200-positive mantle cell lymphoma (MCL) cases from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

    <p>Higher overall leukocyte count (C)</p> Signup and view all the answers

    Which of the following cell characteristics is less commonly seen in CD200-positive MCL cases?

    <p>Smooth nuclear membranes (B)</p> Signup and view all the answers

    What is the typical prognosis for patients with CD23-positive mantle cell lymphoma (MCL) compared to CD23-negative cases?

    <p>Better prognosis (B)</p> Signup and view all the answers

    In the context of anterior MCL cases, which expression pattern is most common for CD200?

    <p>76% are positive for CD200 (A)</p> Signup and view all the answers

    What is the purpose of the MIPI in the context of Mantle Cell Lymphoma?

    <p>To stratify patients into risk groups based on multiple factors (B)</p> Signup and view all the answers

    Which MIPI group has the highest five-year overall survival rate?

    <p>Low-risk group (C)</p> Signup and view all the answers

    What does the biological MIPI (MIPI-b) add to enhance its prognostic power?

    <p>Ki67 proliferation index (C)</p> Signup and view all the answers

    What does a TP53 mutation indicate in patients with Mantle Cell Lymphoma?

    <p>Shorter median overall survival (B)</p> Signup and view all the answers

    What factor is a strong negative prognostic indicator for overall survival in Mantle Cell Lymphoma?

    <p>Early disease progression within 24 months (C)</p> Signup and view all the answers

    How does the combined MIPI (MIPI-c) improve upon the standard MIPI?

    <p>By integrating the Ki67 index for better discrimination (A)</p> Signup and view all the answers

    What percentage represents the overall survival rate for high-risk patients according to the MIPI-c?

    <p>17% (B)</p> Signup and view all the answers

    What is a common characteristic associated with patients who have a TP53 mutation?

    <p>Ki67 index greater than 30% (C)</p> Signup and view all the answers

    Which feature is NOT associated with poor outcomes in relapsed/refractory mantle cell lymphoma treated with BTK inhibitors?

    <p>Ki67 index less than 50% (A)</p> Signup and view all the answers

    What was the observed overall response rate (ORR) for patients with blastoids morphology treated with BTK inhibitors?

    <p>50% (C)</p> Signup and view all the answers

    What percentage of patients aged over 65 showed an overall response rate when treated with the combination of ibrutinib and rituximab for two years?

    <p>96% (A)</p> Signup and view all the answers

    Which of the following therapeutic approaches is NOT mentioned as a novel strategy for patients who progress on BTK inhibitors?

    <p>Bite therapy (B)</p> Signup and view all the answers

    What is the median progression-free survival (PFS) rate for patients with TP53 mutations treated with BTK inhibitors?

    <p>4 months (D)</p> Signup and view all the answers

    Which patient characteristic is associated with inferior outcomes in mantle cell lymphoma?

    <p>Ki67 index greater than or equal to 50% (C)</p> Signup and view all the answers

    Which of the following first-line treatment options is NOT typically included in chemoimmunotherapy regimens for mantle cell lymphoma?

    <p>Acalabrutinib (D)</p> Signup and view all the answers

    What is the relationship between high-risk s-MIPI scores and treatment outcomes in relapsed/refractory MCL?

    <p>They are associated with a decreased overall response rate (C)</p> Signup and view all the answers

    Study Notes

    Mantle Cell Lymphoma

    • Mantle cell lymphoma (MCL) is a chronic B-lineage lymphoproliferative disorder.
    • Characterized by variable cytological and histological features, with a distinctive cytogenetic and molecular genetic defect.
    • Although histologically low-grade, it has an intermediate prognosis, with a median survival of only 3-4 years.
    • Generally considered incurable, and shows an increased incidence associated with a family history of MCL or other non-Hodgkin lymphomas.
    • Characterized by the t(11;14) translocation leading to cyclin D1 overexpression.
    • Shows significant clinical and biological heterogeneity, ranging from indolent non-nodal leukemic variants to highly aggressive blastoid variants.
    • Risk stratification at diagnosis is essential for optimal treatment approach.

    Clinical Presentation

    • Primarily affects middle-aged and older individuals, with a median age of 60 years.
    • Marked male predominance.
    • Usually presents with advanced stage disease, often exhibiting lymphadenopathy and splenomegaly.
    • Extranodal involvement is common, including Waldeyer's ring, lung, pleura, and the gastrointestinal tract.
    • Peripheral blood involvement occurs in about two-thirds of patients, associated with a worse prognosis.
    • Leukemic non-nodal mantle cell lymphoma, usually involving the spleen, tends to be clinically indolent.
    • Central nervous system disease may be more likely in patients with peripheral blood involvement.

    Diagnosis

    • Peripheral blood cytopenias (due to marrow infiltration) and circulating lymphoma cells may be present.
    • Mantle cell lymphoma cells exhibit significant pleomorphism, typically medium-sized with irregular nuclei.
    • Some cells may show inconspicuous nucleoli or pronounced nuclear indentations/clefts.
    • Cytoplasmic vacuoles and rarely, cytoplasmic granules may be present.
    • Chromatin pattern can vary, with some cells exhibiting a diffuse pattern.
    • Blastoid variant (comprising 10-20% of cases) shows predominantly diffuse chromatin pattern, resembling acute lymphoblastic leukemia (ALL) cells or showing more mature features.
    • Bone marrow infiltration is frequent (up to 80% of patients). Infiltration patterns include interstitial/focal, nodules or irregularly shaped infiltrates, etc.
    • Trephine biopsy sections display lymphoma cells with regular round nuclei or irregular, cleaved nuclei, and relatively dense chromatin.

    Immunophenotype

    • Characteristic immunophenotype includes expression of B-cell-associated antigens (CD19, CD20, CD22, CD24, CD79a), CD5, CD79b, FMC7, and BCL2.
    • CD10, CD11c, CD103, and BCL6 are typically not expressed.
    • CD20 expression is strong, often stronger than CD19.
    • CD5 expression is common, but 10-15% of patients lack CD5 expression.
    • CD23 expression is variable (generally weak).
    • Immunophenotyping is crucial for differentiating MCL from other B-cell malignancies.

    Cytogenetic Abnormalities

    • Hallmark cytogenetic abnormality is t(11;14)(q13;q32), leading to dysregulation of the CCND1 gene (encoding cyclin D1), bringing CCNDI into proximity with the IGH locus, leading to cyclin D1 overexpression.
    • This rearrangement is not specific to Mantle Cell Lymphoma, but diagnostic in the appropriate clinical and histological context, which includes multiple myeloma.
    • Additional cytogenetic abnormalities (deletions 1p, 6q, 9p, 11q, and 13q; gains in chromosomes 3 and 12) are also common.

    Molecular Genetic Features

    • MCL cells typically exhibit unmutated IGHV genes, indicating a pre-germinal center origin.
    • A significant minority exhibit IGHV somatic hypermutation, correlating with predominantly non-nodal disease and can include a subgroup of patients with indolent disease.
    • Common secondary genetic abnormalities include gains of MYC, CDK2, CDKN1B, and MDM2, and losses of RB1, CDKN2A, ATM, and TP53.
    • Mutations in TP53, CDKN2A, and CDKN2C are specifically associated with the blastoid variant and poorer prognosis.
    • ATM function loss may occur through point mutation or deletion, impacting both alleles in most cases with del(11)(q23).

    Pitfalls

    • MCL is a differential diagnosis for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) due to shared CD5 positivity.
    • Most MCL cases have intermediate lymphocytes and centrocytes with irregular nuclear contours, but some MCL cases exhibit small sized cells resembling CLL/SLL making distinction challenging.
    • Immunophenotyping and genetic analysis are crucial for accurate diagnosis.
    • MCL is typically positive for cyclin D1 and SOX11, markers that are negative in CLL/SLL.
    • The t(11;14) translocation characteristic of MCL is absent in CLL/SLL.

    CD23-Positive Mantle Cell Lymphoma

    • While CD23 positivity is typically associated with CLL/SLL, approximately 13% of MCL cases are weakly positive for CD23.
    • CD23-positive cases often have increased leukocyte count, bone marrow involvement, and leukemic presentation, similar to CLL.
    • CD23-positive MCL is frequently associated with CD200 positivity and weak SOX11 expression.
    • Despite leukemic presentation, CD23-positive MCL shows a better prognosis compared to CD23-negative MCL.

    CD200 Expression

    • CD200 is a marker for CLL/SLL, but a small subset of MCL cases express CD200.
    • Approximately 4% of MCL cases are CD200-positive, most also being positive for CD23.
    • CD200-positive MCL has distinct features: only 24% express SOX11, 39% exhibit round nuclear contours similar to CLL, and 44% present as a non-nodal leukemic variant of MCL.
    • These cases are frequently associated with IGHV-mutated status, indicative of a potentially more indolent clinical course.

    Mantle Cell Lymphoma International Prognostic Index (MIPI)

    • MIPI is a key prognostic tool for MCL, incorporating age, ECOG Performance Status, lactate dehydrogenase level, and white blood cell count, stratifying patients into low, intermediate, and high-risk groups.
    • Simplified MIPI (s-MIPI) is for routine use. The biological MIPI (MIPI-b) adds the Ki67 proliferation index for improved power.
    • Five-year overall survival (OS) rates for low, intermediate, and high-risk groups are 83%, 63%, and 34%, respectively.
    • Combined MIPI (MIPI-c) integrates the Ki67 index with standard MIPI score for greater discriminatory power.
    • Four risk groups (low, low-intermediate, high-intermediate, and high-risk) show 5-year OS rates of 85%, 72%, 43%, and 17%, respectively.

    TP53 Aberration

    • TP53 aberrations (deletions [del17p] and/or mutations) are important prognostic factors in MCL.
    • High TP53 expression is linked to inferior time-to-treatment failure and overall survival.
    • Patients harboring TP53 mutations are frequently enriched for higher Ki67 index (>30%), blastoid morphology, and a high-risk MIPI, with a short median OS (1.8 years).
    • Only the MIPI-c high-risk group and TP53 mutation group exhibit independent prognostic significance for overall survival, in multivariable analysis.

    Early Disease Progression

    • Early disease progression (within 24 months) is a strong negative prognostic marker for OS.
    • A recent study observed outcomes based on relapse after intensive induction and autologous stem cell transplantation.
    • The impact of relapse was notably greater for patients who relapsed within 6 months.

    Prognostic Factors in Relapsed/Refractory MCL

    • Several factors correlate with poor outcomes in relapsed/refractory MCL treated with BTK inhibitors, these factors include high-risk s-MIPI score, blastoid morphology, and TP53 mutations.
    • Patients with these features show overall response rates (ORR) of about 55%, 50%, and 55%, respectively, and median progression-free survival (PFS) of 6.5 months, 5 months, and 4 months, respectively.
    • Patients with a Ki67 index greater than or equal to 50% are associated with inferior outcomes, characterized by lower response rates and shorter survival.

    New Treatment Strategies

    • Chemoimmunotherapy regimens are standard first-line treatments for naïve MCL.
    • A subset of patients with indolent disease may be observed, but most require therapy.
    • Current treatments incorporate BTK inhibitors (e.g., ibrutinib) in the absence of chemotherapy.
    • The combination of ibrutinib and rituximab for two years followed by ibrutinib continuation demonstrates a high overall response rate (>96%) in patients over 65.
    • Beyond BTK inhibitors, new therapies are needed for patients who progress, focusing on CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates, and next-generation small molecule inhibitors.

    Novel Therapeutic Approaches

    • Various novel targeted therapies are currently under investigation for MCL.
    • These therapies show distinct mechanisms of action and potential for overcoming resistance to current treatments. قيم السمنار من ١٠٠

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    New Directions in Mantle Cell Lymphoma PDF

    Description

    Explore the complexities of mantle cell lymphoma (MCL), a chronic B-lineage lymphoproliferative disorder. This quiz covers its clinical presentation, prognostic factors, and key genetic characteristics, such as the t(11;14) translocation. Understand the need for risk stratification and the challenges in treatment options associated with this lymphoma.

    More Like This

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser